Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Clinical Trial

Reuters11-05

<a href="https://laohu8.com/S/ANIX">Anixa Biosciences</a> Advances Breast Cancer Vaccine to Phase 2 Clinical Trial

Anixa Biosciences Inc. has announced the execution of a data transfer agreement with Cleveland Clinic, marking a key step in the process of transferring the investigational new drug (IND) sponsorship for its breast cancer vaccine clinical trial. This agreement will facilitate the transfer of all relevant Phase 1 clinical trial data to Anixa, as the company prepares to assume full sponsorship of the IND and advance the vaccine to a Phase 2 clinical trial. Enrollment for the Phase 1 trial has been completed, with encouraging immune response data observed. The final Phase 1 data will be presented by Cleveland Clinic at the San Antonio Breast Cancer Symposium on December 11. The breast cancer vaccine, developed in collaboration with Cleveland Clinic, targets α-lactalbumin, a protein associated with lactation that is also present in many breast cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA15984) on November 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581773325?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581773325","market":"nz","top_or_hot":-1,"title":"Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Clinical Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ANIX\">Anixa Biosciences</a> Advances Breast Cancer Vaccine to Phase 2 Clinical Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Anixa Biosciences Inc. has announced the execution of a data transfer agreement with Cleveland Clinic, marking a key step in the process of transferring the investigational new drug (IND) sponsorship for its breast cancer vaccine clinical trial. This agreement will facilitate the transfer of all relevant Phase 1 clinical trial data to Anixa, as the company prepares to assume full sponsorship of the IND and advance the vaccine to a Phase 2 clinical trial. Enrollment for the Phase 1 trial has been completed, with encouraging immune response data observed. The final Phase 1 data will be presented by Cleveland Clinic at the San Antonio Breast Cancer Symposium on December 11. The breast cancer vaccine, developed in collaboration with Cleveland Clinic, targets α-lactalbumin, a protein associated with lactation that is also present in many breast cancers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA15984) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ANIX\">Anixa Biosciences</a> Advances Breast Cancer Vaccine to Phase 2 Clinical Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Anixa Biosciences Inc. has announced the execution of a data transfer agreement with Cleveland Clinic, marking a key step in the process of transferring the investigational new drug (IND) sponsorship for its breast cancer vaccine clinical trial. This agreement will facilitate the transfer of all relevant Phase 1 clinical trial data to Anixa, as the company prepares to assume full sponsorship of the IND and advance the vaccine to a Phase 2 clinical trial. Enrollment for the Phase 1 trial has been completed, with encouraging immune response data observed. The final Phase 1 data will be presented by Cleveland Clinic at the San Antonio Breast Cancer Symposium on December 11. The breast cancer vaccine, developed in collaboration with Cleveland Clinic, targets α-lactalbumin, a protein associated with lactation that is also present in many breast cancers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA15984) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIX","symbol_name":"Anixa Biosciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL25rKLf:1","article_id":"2581773325","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581773325","pubTimestamp":1762350923,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Anixa Biosciences Inc. has announced the execution of a data transfer agreement with Cleveland Clinic, marking a key step in the process of transferring the investigational new drug  sponsorship for its breast cancer vaccine clinical trial. This agreement will facilitate the transfer of all relevant Phase 1 clinical trial data to Anixa, as the company prepares to assume full sponsorship of the IND and advance the vaccine to a Phase 2 clinical trial. Enrollment for the Phase 1 trial has been completed, with encouraging immune response data observed. The final Phase 1 data will be presented by Cleveland Clinic at the San Antonio Breast Cancer Symposium on December 11. The breast cancer vaccine, developed in collaboration with Cleveland Clinic, targets α-lactalbumin, a protein associated with lactation that is also present in many breast cancers.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANIX":"Anixa Biosciences","BK4139":"生物科技"},"translate_title":"Anixa Biosciences将乳腺癌疫苗推进至2期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIX":0.9},"content_text":"Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Clinical Trial\n    \n\n        Anixa Biosciences Inc. has announced the execution of a data transfer agreement with Cleveland Clinic, marking a key step in the process of transferring the investigational new drug (IND) sponsorship for its breast cancer vaccine clinical trial. This agreement will facilitate the transfer of all relevant Phase 1 clinical trial data to Anixa, as the company prepares to assume full sponsorship of the IND and advance the vaccine to a Phase 2 clinical trial. Enrollment for the Phase 1 trial has been completed, with encouraging immune response data observed. The final Phase 1 data will be presented by Cleveland Clinic at the San Antonio Breast Cancer Symposium on December 11. The breast cancer vaccine, developed in collaboration with Cleveland Clinic, targets α-lactalbumin, a protein associated with lactation that is also present in many breast cancers.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA15984) on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581773325","isCrawlerRequest":true}